Pre-emptive use of glucose 5% as the standard drug solvent reduces hypernatremia in critically ill patients
Clinical Kidney Journal · 01.11.2024 · 17 (11)
DOI: 10.1093/ckj/sfae328 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Kidney Journal, online erschienen am 04.11.2024. Verfasst von Jan-Hendrik B Hardenberg und 12 weiteren Autor:innen. Beteiligte Einrichtung: Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Department of Nephrology and M…. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Charité—Universitätsmedizin Berlin, German Research Foundation.
Abstract (Originalsprache)
Background
Hypernatremia presents a common complication in intensive care unit (ICU) patients, associated with increased mortality and length of stay. This study investigates the effect of sodium chloride 0.9% compared with glucose 5% solution as the standard intravenous drug diluent on the prevalence of hypernatremia in a medical ICU.
Methods
This is a retrospective before-and-after study comparing two consecutive patient groups before and after the standard drug solvent was changed from sodium chloride 0.9% to glucose 5% solution for compatible medications. A total of 265 adult COVID-19 patients admitted between October 2020 and March 2021 to the study ICU were included, with 161 patients in the timeframe when sodium chloride 0.9% was employed as the standard drug solvent and 104 patients when glucose 5% was used. Routine sodium measurements from arterial and venous blood gases, along with heparinized lithium plasma, were analyzed. The daily sodium concentrations and the prevalence of severe hypernatremia (>150 mmol/l) were assessed during the first 8 days after ICU admission.
Results
Baseline characteristics were similar between the two groups. The cumulative volume of intravenous drug diluents was comparable. In the glucose 5% group, about half of the total drug diluent volume was glucose 5% [mean (SD): 2251.6 (2355.4) ml], compared to 135.0 (746.9) ml (P < .001) in the control group. Average sodium concentrations diverged after day two, with the glucose 5% group consistently showing lower sodium levels (mean difference of ∼2.5 mmol/l). Severe hypernatremia occurred less frequently in the glucose 5% group (6.6% vs. 20%).
Conclusion
Glucose 5% solution as the standard intravenous drug solvent significantly reduced sodium concentrations and the occurrence of severe hypernatremia. This simple modification in solvent choice may serve as a preventive strategy against hypernatremia in the ICU. Further prospective research is necessary to determine associated clinical outcomes.
Trial registration
The trial was registered in the German Clinical Trials Register (DRKS00031877).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Department of Nephrology and Medical Intensive Care, Augustenburger Platz 1, Berlin, Germany.
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Junior Digital Clinician Scientist Program, Charitéplatz 1, Berlin, Germany.
- Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Institute of Biometry and Clinical Epidemiology, Charitéplatz 1, Berlin, Germany.
- Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Department of Infectious Diseases, Respiratory Medicine and Critical Care Medicine, Charitéplatz 1,…
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Digital Clinician Scientist Program, Charitéplatz 1, Berlin, Germany.
- Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Institute of Medical Informatics, Charitéplatz 1, Berlin, Germany.
ORCID-Profile: Jan-Hendrik B Hardenberg, Julius Valentin Kunz, Kai-Uwe Eckardt
Förderung
- Charité—Universitätsmedizin Berlin
- German Research Foundation
Zitieren
APA
Hardenberg, J. B., Kunz, J. V., Rubarth, K., Mittermaier, M., Pigorsch, M., Balzer, F., Witzenrath, M., Hinz, R. M., Körner, R., Eckardt, K. U., Knauf, F., Hinrichs, C., & Enghard, P. (2024). Pre-emptive use of glucose 5% as the standard drug solvent reduces hypernatremia in critically ill patients. Clinical Kidney Journal, 17(11). https://doi.org/10.1093/ckj/sfae328
Vancouver
Hardenberg JB, Kunz JV, Rubarth K, Mittermaier M, Pigorsch M, Balzer F, et al. Pre-emptive use of glucose 5% as the standard drug solvent reduces hypernatremia in critically ill patients. Clinical Kidney Journal. 2024;17(11). doi:10.1093/ckj/sfae328
BibTeX
@article{Hardenberg2024,
author = {Hardenberg, Jan-Hendrik B and Kunz, Julius Valentin and Rubarth, Kerstin and Mittermaier, Mirja and Pigorsch, Mareen and Balzer, Felix and Witzenrath, Martin and Hinz, Ricarda Merle and Körner, Roland and Eckardt, Kai-Uwe and Knauf, Felix and Hinrichs, Carl and Enghard, Philipp},
title = {Pre-emptive use of glucose 5% as the standard drug solvent reduces hypernatremia in critically ill patients},
journal = {Clinical Kidney Journal},
year = {2024},
volume = {17},
number = {11},
doi = {10.1093/ckj/sfae328}
}
EUVIMED